These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28026908)

  • 61. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
    Dungan KM; Weitgasser R; Perez Manghi F; Pintilei E; Fahrbach JL; Jiang HH; Shell J; Robertson KE
    Diabetes Obes Metab; 2016 May; 18(5):475-82. PubMed ID: 26799540
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
    Wysham CH; Rosenstock J; Vetter ML; Dong F; Öhman P; Iqbal N
    Diabetes Obes Metab; 2018 Jan; 20(1):165-172. PubMed ID: 28685973
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
    Pratley RE; Eldor R; Raji A; Golm G; Huyck SB; Qiu Y; Sunga S; Johnson J; Terra SG; Mancuso JP; Engel SS; Lauring B
    Diabetes Obes Metab; 2018 May; 20(5):1111-1120. PubMed ID: 29266675
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Concordance the hemoglobin glycation index with glycation gap using glycated albumin in patients with type 2 diabetes.
    Kim MK; Jeong JS; Kwon HS; Baek KH; Song KH
    J Diabetes Complications; 2017 Jul; 31(7):1127-1131. PubMed ID: 28487124
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Psyllium fiber improves glycemic control proportional to loss of glycemic control: a meta-analysis of data in euglycemic subjects, patients at risk of type 2 diabetes mellitus, and patients being treated for type 2 diabetes mellitus.
    Gibb RD; McRorie JW; Russell DA; Hasselblad V; D'Alessio DA
    Am J Clin Nutr; 2015 Dec; 102(6):1604-14. PubMed ID: 26561625
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Insights into optimal basal insulin titration in type 2 diabetes: Results of a quantitative survey.
    Berard L; Bonnemaire M; Mical M; Edelman S
    Diabetes Obes Metab; 2018 Feb; 20(2):301-308. PubMed ID: 28719066
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Impact of deprivation, ethnicity, and insulin pump therapy on developmental trajectories of diabetes control in COB type 1 diabetes.
    Viner RM; White B; Amin R; Peters C; Khanolkar A; Christie D; Hindmarsh PC
    Pediatr Diabetes; 2017 Aug; 18(5):384-391. PubMed ID: 27534520
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Continuation or discontinuation of pioglitazone when starting bedtime insulin in patients with poorly controlled type 2 diabetes in an inner-city population.
    Mojtahedzadeh M; Lee ML; Friedman TC
    J Diabetes Complications; 2015; 29(8):1248-52. PubMed ID: 26215435
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose-lowering interventions.
    Roussel R; Steg PG; Mohammedi K; Marre M; Potier L
    Diabetes Obes Metab; 2018 Feb; 20(2):238-244. PubMed ID: 28597588
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.
    Tanaka S; Suzuki K; Aoki C; Niitani M; Kato K; Tomotsune T; Aso Y
    Diabetes Technol Ther; 2014 Dec; 16(12):840-5. PubMed ID: 25144424
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly.
    Shaw JE; Gallwitz B; Han J; Hardy E; Schernthaner G
    Diabetes Obes Metab; 2017 Dec; 19(12):1793-1797. PubMed ID: 28573708
    [TBL] [Abstract][Full Text] [Related]  

  • 73. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
    Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
    Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
    Yu Pan C; Han P; Liu X; Yan S; Feng P; Zhou Z; Lv X; Tian H; Jin Kui Y; Su B; Shang S; Niemoeller E
    Diabetes Metab Res Rev; 2014 Nov; 30(8):726-35. PubMed ID: 24639432
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Characteristics of Patients with Type-1 or Type-2 Diabetes Receiving Insulin Glargine U300: An Analysis of 7268 Patients Based on the DPV and DIVE Registries.
    van Mark G; Lanzinger S; Sziegoleit S; Putz FJ; Durmaz M; Borscheller M; Danne T; Seufert J; Holl RW; Bramlage P
    Adv Ther; 2019 Jul; 36(7):1628-1641. PubMed ID: 31119688
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes.
    Riddle MC; Bolli GB; Home PD; Bergenstal RM; Ziemen M; Muehlen-Bartmer I; Wardecki M; Vinet L; Jeandidier N; Yki-Järvinen H
    Diabetes Technol Ther; 2016 Apr; 18(4):252-7. PubMed ID: 26840338
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin.
    Freemantle N; Danchin N; Calvi-Gries F; Vincent M; Home PD
    Diabetes Obes Metab; 2016 Feb; 18(2):152-8. PubMed ID: 26511332
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes.
    Umpierrez GE; O'Neal D; DiGenio A; Goldenberg R; Hernandez-Triana E; Lin J; Park CY; Renard E; Kovatchev B
    Diabetes Obes Metab; 2017 Sep; 19(9):1317-1321. PubMed ID: 28256054
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC; Cull CA; Frighi V; Holman RR
    JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.